How has been the historical performance of Biogen Pharma?

Answer:The historical performance of Biogen Pharma has shown significant fluctuations over the years, particularly in its revenue and profitability metrics.

Breakdown:
Biogen Pharma's net sales have been inconsistent, with no sales recorded from March 2023 to March 2025, following a modest increase to 2.47 Cr in March 2022 from 1.62 Cr in March 2021. Other operating income peaked at 2.38 Cr in March 2024 but dropped to 0.84 Cr in March 2025. Total operating income followed a similar trend, reaching 2.38 Cr in March 2024 before declining to 0.84 Cr in March 2025. The company's total expenditure, excluding depreciation, was 1.13 Cr in March 2025, up from 0.45 Cr in March 2024, leading to an operating profit (PBDIT) of -0.29 Cr in March 2025, a stark contrast to the 1.93 Cr profit in March 2024. This resulted in a profit before tax of -0.29 Cr in March 2025, down from 1.93 Cr the previous year. The net profit also reflected this downturn, showing a loss of -0.29 Cr in March 2025 compared to a profit of 1.93 Cr in March 2024. On the balance sheet, total assets increased to 56.82 Cr in March 2024 from 54.83 Cr in March 2023, while total liabilities also rose to 56.82 Cr in March 2024. The cash flow from operating activities remained stable at 1.00 Cr for both March 2024 and March 2023, but cash flow from investing activities showed a negative trend, indicating increased outflows. Overall, Biogen Pharma's financial performance has been marked by volatility, particularly in profitability and revenue generation.